Compared side by side

Retatrutide vs orforglipron: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Orforglipron acts on one receptor, GLP-1, and is a small molecule (not a peptide) taken as a daily tablet; retatrutide is a weekly shot that activates three, GLP-1, GIP and glucagon. Orforglipron is FDA-approved, as Foundayo since April 2026, and retatrutide isn’t approved yet. In their own trials, orforglipron’s top dose averaged about 11% weight loss at 72 weeks, and retatrutide’s top dose about 25–28% at 80 weeks in phase 3.

Side by side

ComparedRetatrutideOrforglipron
CategoryMetabolic & GLP-1Metabolic & GLP-1
Also known asLY3437943Foundayo, LY3502970, Orfo
What it isThe first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice).A GLP-1 drug in a once-daily tablet that is not a peptide, so it comes with no fasting or water rules: Lilly's Foundayo, FDA-approved in April 2026 for weight management.
How it worksTriple GIP/GLP-1/glucagon receptor agonist. Produces large weight loss through appetite suppression and improved metabolic function; the glucagon arm adds energy expenditure, shown so far in mice. Its trials step the dose up every 4 weeks because GI side effects rise with the dose; in phase 2 they were milder with a 2 mg start than a 4 mg one.Small-molecule (non-peptide) GLP-1 receptor agonist taken as a daily tablet. Because it is a small molecule it is absorbed without the fasting and water rules of oral semaglutide: the label puts its absolute bioavailability at 77% and lets it be taken with or without food. It reduces food intake, likely by lowering appetite, and delays stomach emptying, most after the first dose; in animal studies it reached and activated brain regions that regulate appetite. FDA-approved on April 1, 2026, as Foundayo for chronic weight management, at 0.8 to 17.2 mg once daily.
Commonly reportedAppetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. Its top dose averaged about 25–28% weight loss at 80 weeks in phase 3; it isn't approved yet.The easy routine is the main draw, with nausea, constipation or burping mostly in the weeks after each step-up. Its top dose averaged about 11% weight loss at 72 weeks in its main trial.
Studied rangeResearch range: 1–12 mg, starting dose 2 mg. Studied in research — not a recommendation.FDA label: 0.8–17.2 mg, starting dose 0.8 mg.
How oftenWeeklyDaily
Half-life~6 days (measured in early trials in people)~29–49 hours (FDA label; steady levels after about a week of daily tablets)
RouteSubQ injectionOral tablet
Typical runPhase 3 trials use continuous dosing. Community mirrors this — long-term with slow titration.FDA-approved for long-term use alongside diet and activity. ATTAIN-MAINTAIN tested it as the follow-on to weekly injections for keeping weight off.
EvidenceEstablished: clinical trials or FDA-approved use existsEstablished: clinical trials or FDA-approved use exists
Common side effectsNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal painNausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide or orforglipron? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

Retatrutide

  • Day 1–28 · 2 mg Triple-agonist is kicking in
  • Day 29–84 · 4 mg Dose-response steepens
  • Day 60+ · 9 mg Watch for dysesthesia at higher doses
  • Day 84+ This is a maintenance medication, not a course
  • Day 85–168 · 8 mg Higher steps: strong satiety
  • Day 169–336 No plateau yet at week 48
  • Day 337–476 Phase 3 territory: the headline numbers

Every card for retatrutide, with its sources

Orforglipron

  • Day 1–30 · 0.8 mg The 0.8 mg start
  • Day 31–60 · 2.5 mg 2.5 mg, the second step
  • Day 61+ · 5.5 mg 5.5 mg, the first maintenance dose
  • Day 91+ · 9 mg 9 mg, an optional step
  • Day 121+ · 14.5 mg 14.5 mg, the step before the top
  • Day 151+ · 17.2 mg 17.2 mg, the top dose

Every card for orforglipron, with its sources

Questions people ask

How long do retatrutide and orforglipron last?

The half-life of retatrutide is ~6 days (measured in early trials in people). The half-life of orforglipron is ~29–49 hours (FDA label; steady levels after about a week of daily tablets).

How often are retatrutide and orforglipron taken?

Retatrutide: weekly. Route: SubQ injection. Orforglipron: daily. Route: Oral tablet.

How are retatrutide and orforglipron dosed in research?

The research range for retatrutide is 1–12 mg, with a 2 mg starting dose. Studied in research — not a recommendation. The FDA label range for orforglipron is 0.8–17.2 mg, with a 0.8 mg starting dose.

What are the common side effects of retatrutide and orforglipron?

For retatrutide, the library lists: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, abdominal pain. For orforglipron: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, burping.

Each one in full

Track it in the app

PepVault for iPhone

Taking retatrutide or orforglipron? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo